Newsround

1 July 2013 0

Selected reports edited by Janet Fricker ABVD less effective and more toxic in older patients =>Journal of Clinical Oncology In patients aged 60 years or older with Hodgkin lymphoma (HL), four cycles of ABVD is [more]

Time to act on trials

1 January 2013 0

Many of the worst economic and bureaucratic burdens that have proved such a deterrent to multi-country clinical trials look set to be addressed with the overhaul of the EU Clinical Trials Directive, but should we [more]

Me and my cancer

1 January 2013 0

Journalists who write about their own cancer journeys are able to convey important insights in a language that people understand – and are eager to read It is not surprising that a lot of journalists [more]

Lungscape: a living lung laboratory

1 November 2012 0

The potential for personalising lung cancer therapies is expanding rapidly. The challenge now is how to turn that potential into reality as fast as possible so patients can reap the benefits. A network of cancer [more]

Jaap Verweij: an intelligent approach to drug

1 May 2010 0

Jaap Verweij, head of medical oncology and an early-phase trials expert at the Erasmus University Medical Centre in Rotterdam invites you to reappraise the way we are going about improving cancer therapies. Download full article

1 2
UA-77507851-1